Immune factors influencing ethnic disparities in kidney transplantation outcomes

Expert Review of Clinical Immunology

Volumn 7, Issue 6, 2011, Pages 769-778

  Padiyar, Aparna ^a   Hricik, Donald E ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

acute rejection; chemokines; cytokines; ethnicity; graft survival; immune responses; kidney transplantation; race

Indexed keywords

CHEMOKINE; CYTOKINE;

AFRICAN AMERICAN; ALLOIMMUNITY; CAUCASIAN; ETHNIC DIFFERENCE; ETHNICITY; GRAFT RECIPIENT; HISTOCOMPATIBILITY; HUMAN; IMMUNE RESPONSE; KIDNEY TRANSPLANTATION; OUTCOMES RESEARCH; REVIEW; SOCIOECONOMICS;

AFRICAN AMERICANS; CYTOKINES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; KIDNEY; KIDNEY TRANSPLANTATION; MALE; SOCIOECONOMIC FACTORS; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

EID: 80054924994     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/eci.11.32     Document Type: Review

References (97)

1. Wolfe RA, Oji AO, Ettenger RE, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N. Engl. J. Med. 341, 1725-1730 (1999)
2. Katznelson S, Gjertson DW, Cecka JM. The effect of race and ethnicity on kidney allograft out come. In: Clinical Transplants 1995. Cecka JM, Terasaki PI (Eds). UCLA Tissue Typing Laboratory, CA, USA, 379-394 (1996)
3. Isaacs RB, Nock SL, Spencer CE, et al. Racial disparities in renal transplant outcomes. Am. J. Kidney Dis. 34, 706-712 (1999)
4. Meier-Kriesche HU, Ojo AO, Leichtman AB, et al. Effect of mycophenolate mofetil on long-term outcomes in African American renal transplant recipients. J. Am. Soc. Nephrol. 11, 2366-2370 (2000)
5. Mizutani K. HLA mismatches and PRA in kidney retransplants. Clin. Transpl. 21, 19-27 (2007)
6. 2009 Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1999-2008. Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation, Rockville, MD; United Network for Organ Sharing, Richmond, VA; University Renal Research and Education Association, Ann Arbor, MI, USA
7. Kallich JD, Adams JL, Barton PL, Spritzer KL. Access to cadaveric kidney transplantation. Santa Monica, CA, USA, RAND (1993)
8. Padiyar A, Augustine JJ, Bodziak KA, Aeder M, Schulak JA, Hricik DE. Influence of African-American ethnicity on acute rejection after early steroid withdrawal in primary kidney transplant recipients. Transplant. Proc. 42, 1643-1647 (2010)
9. Scantlebury V, Gjertson D, Eliaszi M, et al. Effect of HLA mismatch in African- Americans. Transplantation 65, 586-588 (1998)
10. Meier-Kriesche HU, Ojo AO, Leichtman AB, et al. Interaction of mycophenolate mofetil and HLA matching on renal allograft survival. Transplantation 71, 398-401 (2001)
11. Schnitzler MA, Hollenbeak CS, Cohen DS, et al. The economic implications of HLA matching in cadaveric renal transplantation. N. Engl. J. Med. 341, 1440-1446 (1999)
12. Meier-Kriesche HU, Scornik JC, Susskind B, Rehman S, Schold JD. A lifetime versus a graft life approach redefines the importance of HLA matching in kidney transplant patients. Transplantation 88, 23-29 (2009)
13. Young CJ, Gaston RS. Renal transplantation in African-American Americans. N. Engl. J. Med. 343, 1545-1552 (2000)
14. Evans RW. Money matters: should ability to pay ever be a consideration in gaining access to transplantation? Transplant. Proc. 21, 3419-3423 (1989)
15. McCormick PA, O'Rourke M, Carey D, Laffoy M. Ability to pay and geographical proximity influence access to liver transplantation even in a system with universal access. Liver Transpl. 10, 1422-1427 (2004)
16. Ayanaian J, Cleary P, Weissman J, et al. The effect of patient's preference on racial differences in access to renal transplantation. N. Engl. J. Med. 341, 1661-1669 (1999)
17. Bach P, Pham H, Schrag D, et al. Primary care physicians who treat African- Americans and Whites. N. Engl. J. Med. 351, 575-584 (2004)
18. Ozminkowski R, White A, Hassol A, et al. What if socioeconomics made no difference: access to cadaver kidney transplant as an example. Med. Care. 36, 1398-1406 (1998)
19. Sequist TD, Narva AS, Stiles SK, Karp SK, Cass A, Ayanian JZ. Access to renal transplantation among American Indians and Hispanics. Am. J. Kidney Dis. 44, 344-352 (2005)
20. Julapalli VR, Kramer JR, El-Serag HB. Evaluation for liver transplantation: adherence to AASLD referral guidelines in a large Veterans Affairs center. Liver Transpl. 11, 1370-1378 (2005)
21. Weng FL, Reese PP, Mulgankar S, Patel AM. Barriers to lving donor kidney transplantation among black or older transplant candidates. Clin. J. Am. Soc. Nephrol. 5, 2338-2347 (2010)
22. Gaston RS, Hudson SL, Deierhoi MH, et al. Improved survival of primary cadaveric renal allografts in blacks with quadruple immunosuppression. Transplantation 53, 103-109 (1992)
23. Neylan JF. Immunosuppressive therapy in high-risk transplant patients: dose-dependent efficacy of mycophenolate mofetil in African-American renal allograft recipients. Transplantation 64, 1277-1282 (1997)
24. Sanders CE, Curtis JJ, Julian BA, et al. Tapering or discontinuing cyclosporine for financial reasons - a single center experience. Am. J. Kidney Dis. 21, 9-15 (1993)
25. Hricik DE, Whalen CC, Lautman J, et al. Withdrawal of steroids after renal transplantation - clinical predictors of outcome. Transplantation 53, 41-45 (1992)
26. Ahsan N, Hricik D, Matas A, Tomlanovich S, Wilkinson A; for the Steroid Withdrawal Study Group. Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil - a prospective randomized study. Transplantation 68, 1865-1874 (1999)
27. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantion 60, 225-232 (1995)
28. Podder H, Podbielski J, Hussein I, Katz S, Van Buren C, Kahan BD. Sirolimus improves the two-year outcome of renal allografts in African-American patients. Transplant. Int. 14, 135-42 (2001)
29. Lindholm A, Welsh M, Rutzky L, Kahan BD. The adverse impact of high cyclosporine clearance rates on the incidences of acute rejection and graft loss. Transplantation 55, 985-993 (1993)
30. Schroeder TJ, Hariharan S, First MR. Variations in bioavailability of cyclosporine and relationship to clinical outcome in renal transplant subpopulations. Transplant. Proc. 27, 837-839 (1995)
31. Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 63, 977-983 (1997)
32. Floyd MD, Gervasini G, Masica AL, et al. Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in basal an induced metabolism of midazolam in European and African American men and women. Pharmacogenetics 13, 595-606 (2003)
33. Zheng HX, Zeevi A, McCurry K, et al. The impact of pharmacogenomic factors on acute persistent rejection in adult lung transplant patients. Transpl. Immunol. 14, 37-42 (2005)
34. Zheng HX, Webber S, Zeevi A, et al. Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am. J. Transplant. 3, 477-483 (2003)
35. Kuehl P, Zhang J, Yin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 27, 383-391 (2001)
36. Bain BJ. Ethnic and sex differences in the total and differential white cell count and platelet count. J. Clin. Pathol. 49, 664-666 (1996)
37. Freedman DS, Gates L, Flanders WD, et al. Black/white differences in leukocyte subpopulations in men. Int. J. Epidemiol. 26, 757-764 (1997)
38. Kerman RH, Floyd M, Van Buren CT, Kahan BD. Improved allograft survival of strong immune responder-high risk recipients with adjuvant antithyocyte globulin therapy. Transplantation 30, 450-454 (1980)
39. Kerman RH, Kimball PM, Van Buren CT, Lewis RM, Kahan BD. Possible contribution of pretransplant immune responder status to renal allograft survival differences of black versus white recipients. Transplantation 51, 338-342 (1991)
40. Hricik DE, Rodriguez V, Riley J, et al. Enzyme linked immunoabsorbent spot assay for interferon-g independently predicts renal function in kidney transplant recipients. Am. J. Transplant. 3, 878-884 (2003)
41. Augustine JJ, Siu D, Clemente M, Schulak JA, Heeger PS, Hricik DE. Pretransplant IFN-g ELISpots are associated with posttransplant renal function in African American renal transplant recipients. Am. J. Transplant. 5, 1971-1975 (2005)
42. Poggio ED, Clemente M, Hricik DE, Heeger PS. Panel of reactive T cells as a measurement of primed cellular alloimmunity in kidney transplant candidates. J. Am. Soc. Nephrol. 17, 564-572 (2006)
43. Augustine JJ, Poggio ED, Clemente M, et al. Hemodialysis vintage, black ethnicity, and pretransplantation antidonor cellular immunity in kidney transplant recipients. J. Am. Soc. Nephrol. 18, 1602-1606 (2007)
44. Yang Y, Wilson JM. CD40 ligand-dependent T cell activation: requirement of B7-CD28 signaling through CD40. Science 273, 1862-1864 (1996)
45. Hutchings A, Purcell WM, Benfield MR. Peripheral blood antigen-presenting cells from African-Americans exhibit increased CD80 and CD 86 expression. Clin. Exp. Immunol. 118, 247-252 (1999)
46. Hutchings A, Purcell WM, Benfield MR. Increased costimulatory responses in African American kidney allograft recipients. Transplantation 71, 692-695 (2001)
47. Inocencio JD, Choi E, Glass DN, Hirsch R. T cell receptor repertoire differences between African Americans and Caucasians associated with polymorphism of the TCRBV3S1 (V b 3.1) gene. J. Immunol. 54, 4836-4841 (1995)
48. Dai Z, Lakkis FG. The role of cyokines, CTLA-4, and costimulation in transplant tolerance and rejection. Curr. Opin. Immunol. 11, 504-508 (1999)
49. Pravica V, Asderakis A, Perrey C, Hajeer A, Sinnott PJ, Hutchinson IV. In vitro production of IFN-g correlates with CA repeat polymorphism in the human IFN-g gene. Eur. J. Immunogenet. 26, 1-3 (1999)
50. Awad MR, El Gamel A, Hasleton P, Turner DM, Sinnott PJ, Hutchinson IV. Genotypic variation in the transforming growth factor-b 1 gene: association with transforming growth factor-b 1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. Transplantation 66, 1014-1020 (1998)
51. Hoffmann SC, Stanley EM, Darrin CE, et al. Association of cytokine polymorphic inheritance and in vitro cytokine production in anti-CD3/CD28- stimulated peripheral blood lymphocytes. Transplantation 72, 1444-1450 (2001)
52. Sankaran D, Asderakis A, Ashraf S, et al. Cytokine gene polymorphisms predict acute graft rejection following renal transplantation. Kidney Int. 56, 281-288 (1999)
53. Asderakis A, Sankaran D, Dyer P, et al. Association of polymorphisms in the human interferon-g and interleukin-10 gene with acute and chronic kidney transplant outcome: the cytokine effect on transplantation. Transplantation 1, 674-677 (2001)
54. Turner D, Grant SC, Yonan X, et al. Cytokine gene polymorphism and heart transplant rejection. Transplantation 64, 776-779 (1997)
55. Holweg CT, Baan CC, Balk AH, et al. The transforming growth factor b1 codon 10 gene polymorphism and accelerated graft vascular disease after clinical heart transplantation. Transplantation 71, 1463-1467 (2001)
56. Awad MR, Webber S, Boyle G, et al. The effect of cytokine gene polymorphisms on pediatric heart allograft outcome. J. Heart. Lung. Transplant. 20, 635-630 (2001)
57. Tambur AR, Ortegel JW, Ben Ari Z, et al. Role of cytokine gene polymorphism in hepatitis C recurrence and allograft rejection among liver transplant recipients. Transplantation 71, 1475-1480 (2001)
58. Miki C, McMaster P, Mayer AD, Iriyarna K, Suzuki H, Buckels JA. Factors predicting perioperative cytokine response in patients undergoing liver transplatnation. Crit. Care Med. 28, 351-428 (2000)
59. Hoffmann SC, Stanley EM, Cox ED, et al. Ethnicity greatly influences cytokine polymorphism distribution. Am. J. Transplant. 2, 560-567 (2002)
60. Cox ED, Hoffmann SC, DiMercurio BS, et al. Cytokine polymorphic analyses indicate ethnic differences in the allelic distribution of interleukin-2 and interleukin-6. Transplantation 72, 720-726 (2001)
61. Delaney NL, Esquenazi V, Lucas DP, Zachary AA, Leffell MS. TNF-a, TGF-b, IL-10, IL-6, and INF-g alleles among African Americans and Cuban Americans. Report of the ASHI Minority Workshops: Part IV. Hum. Immunol. 65, 1413-1419 (2004)
62. Van Parijs L, Perez VL, Abbas AK. Mechanisms of peripheral T cell tolerance. Novartis. Found. Symp. 33, 5-14 (1998)
63. Li Y, Li XC, Zheng XX, Wells AD, Turka LA, Strom TB. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat. Med. 5, 1298-1302 (1999)
64. Marshall SE, McLaren AJ, Haldar NA, Bunce M, Morris PJ, Welsh KI . The impact of recipient cytokine genotype on acute rejection after renal transplantation. Transplantation 70, 1485-1491 (2000)
65. Lowry RP, Konieczny B, Alexander D, et al. Interleukin-10 eliminates anti-CD3 monoclonal antibody-induced mortality and prolongs heart allograft survival in inbred mice. Transplant. Proc. 27, 392-394 (1995)
66. Mottram PL, Han WR, Purcell LJ, McKenzie IF, Hancock WW. Increased expression of IL-4 and IL-10 and decreased expression of IL-2 and interferon-g in long-surviving mouse heart allografts afterbrief CD4-monoclonal antibody therapy. Transplantation 59, 559-565 (1995)
67. Zheng XX, Steele AW, Nickerson PW, Steurer W, Steiger J, Strom TB. Administration of noncytolytic IL-10/ Fc in murine models of lipopolysaccharide-induced septic shock and allogeneic islet transplantation. J. Immunol. 154, 5590-5600 (1995)
68. Hutchings A, Guay-Woodford L, Thomas JM, et al. Association of cytokine single nucleotide polymorphisms with B7 costimulatory molecules in kidney allograft recipients. Pediatr. Transplant. 6, 69-77 (2002)
69. McDaniel DO, Barber WH, Nguyan C, et al. Combined analysis of cytokine genotype polymorphism and the level of expression with allograft function in African-American renal transplant patients. Transplant. Immun. 11, 117-119 (2003)
70. Suthanthiran M, Li B, Song JO, et al. Transforming growth factor b1 hyperexpression in African-American hypertensives: a novel mediator of hypertension and/or target organ damage. Proc. Natl Acad. Sci. USA 97(7), 3479-3484 (2000)
71. Thakkinstian A, Dmitrienko S, Gerbase- DeLima M, et al. Association between cytokine gene polymorphisms and outcome in renal transplantation: a meta-analysis of individual patient data. Nephrol. Dial. Transplant. 23, 3017-3023 (2008)
72. Hancock W, Liqing W, Ye Q, et al. Chemokines and their receptors as markers of allograft rejection and targets for immunosuppression. Curr. Opin. Immunol. 15, 479-486 (2003)
73. Lalor P, Adams DH. Lymphocyte homing to allografts. Transplantation 70, 1131-1139 (2000)
74. DeVries M, Hosiawa KA, Cameron CM, et al. The role of chemokines and chemokine receptors in alloantigen-independent and alloantigen-dependent transplantation injury. Semin. Immunol. 15, 33-48 (2003)
75. Rot A. In situ binding assay for studying chemokine interactions with endothelial cells. J. Immunol. Methods 273, 63-71 (2003)
76. Middleton J, Patterson, AM, Garner L, et al. Leukocyte extravasation: chemokine transport and presentation by the endothelium. Blood 100(12), 3853-3860 (2002)
77. Fukuma N, Akimitsu N, Hamamoto H, et al. A role of the Duffy antigen for the maintenance of plasma chemokine concentrations. Biochem. Biophys. Res. Commun. 303, 137-139 (2003)
78. Dawson T, Lentsch AB, Wang Z, et al. Exaggerated response to endotoxin in mice lacking the Duffy antigen/receptor for chemokines (DARC). Blood 96, 1681-1684 (2000)
79. Peiper S, Wang Z, Kuldeep N, et al. The duffy antigen/receptor for chemokines (DARC) is expressed in endothelial cells of duffy negative individuals who lack the erythrocyte receptor. J. Exp. Med. 18, 1311-1317 (1995)
80. Chaudhuri A, Nielsen S, Eikjaer ML, et al. Detection of Duffy antigen in the plasma membranes and caveolae of vascular endothelial and epithelial cells of noneyrthroid organs. Blood 89, 701-712 (1997)
81. Segerer S, Regele H, Mack M, et al. The Duffy antigen receptor for chemokines is upregulated during acute renal transplant rejection and crescentic glomerulonephritis. Kidney Int. 58, 1546-1556 (2000)
82. Sergerer S, Regele H, Mack M, et al. When renal allografts turn DARC. Transplantation 75, 1030-1034 (2003)
83. Nickel R, Willadsen SA, Friedhoff LR, et al. Determination of Duffy genotypes in three populations of African descent using PCR and sequence specific oligonucleotides. Hum. Immunol. 60, 738-742 (1999)
84. Hadley TJ, Peiper SC. From malaria to chemokine receptor: the emerging physiologic role of the Duffy blood group antigen. Blood 89, 3077-3091 (1997)
85. Danoff TM, Hallows KR, Burns KL, Brayman KL, Feldman HI. Renal allograft survival in African-Americans: influence of the Duffy Blood Group [abstract]. Transplantation 67, S8 (1999)
86. Douzdjian V, Kukuruga DL, Bajjoka IE, Abouljoud MS. The impact of Duffy blood type on renal allograft survival in African Americans [abstract]. Transplantation 69(8), S142 (2000)
87. Akalin E, Neylan JF. The influence of Duffy blood group on renal allograft outcome in African Americans. Transplantation 75, 1496-1500 (2003)
88. Mange KC, Prak EL, Kamoun M, et al. Duffy antigen receptor and genetic susceptibility of African Americans to acute rejection and delayed function. Kidney Int. 66, 1187-1192 (2004)
89. Peiper S, Wang Z, Kuldeep N, et al. The duffy antigen/receptor for chemokines (DARC) is expressed in endothelial cells of duffy negative individuals who lack the erythrocyte receptor. J. Exp. Med. 181, 1311-1317 (1995)
90. Pallet N, Thervet E, Alberti C, et al. Are African Europeans different from African Americans? Am. J. Transplant. 5, 2682-2687 (2005)
91. Young CJ, Gaston RS. Understanding the influence of ethnicity on renal allograft survival. Am. J. Transplant. 5, 2603-2604 (2005)
92. Genovese G, Friedman DJ, Ross MD, et al. Association of tripanolytic APOL1 variants with kidney disease in African Americans. Science 329, 841-845 (2010)
93. Freedman BI, Kopp JB, Langefeld CD, et al. The apolipoprotein L1 (APOL1) gene and diabetic nephropathy in African Americans. J. Am. Soc. Nephrol. 21, 1422-1426 (2010)
94. Reeves-Daniel AM, DePalma JA, Bleyer AJ, et al. The APOL1 gene and allograft survival in kidney transplantation. Am. J. Transplant DOI: 10.1111/j.1600-6143.2011.03513.x (Epub ahead of print) (2011)
95. North American Pediatric Transplant Cooperative Study (NAPRTCS) (2004) www.napartcs.org
96. Clinical Trials in Organ Transplantation (CTOT) www.ctotstudies.org
97. 2009 Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients Annual Report: Transplant Data 1999-2008 http://optn.transplant.hrsa.gov/ar2009/